AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31493863 — intervention group
Group type: EXPERIMENTAL
Intervention: Global rating scores or standardised physical measures
Number of subjects: 361
Study 29304417 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG) measures during motor skill acquisition, consolidation, and interlimb transfer.
Number of subjects: 0
Study 29304417 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in PSI (phase slope index) between premotor, supplementary motor, and primary motor cortex (M1) electrodes.
Number of subjects: 0
Study 29304417 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in PSI between M1 and parietal and primary sensory cortex (S1).
Number of subjects: 0
Study 29304417 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of consolidated interlimb transfer correlated with PSI between bilateral M1s and between S1 and M1 in the non-practiced hemisphere.
Number of subjects: 0
Study 27230903 — intervention group
Group type: EXPERIMENTAL
Intervention: Together at School intervention program
Number of subjects: 3704
Study 27230903 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3704
Study 25422026 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy combined with physical training
Number of subjects: 22
Study 22495117 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.9 µg HA + AS03B (5.93 mg α‐tocopherol) vaccine (6 mo‐9 y)
Number of subjects: 60
Study 22495117 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 µg HA + AS03A (11.86 mg α‐tocopherol) vaccine (10‐17 y)
Number of subjects: 60
Study 20090775 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-pressure method (PPM)
Number of subjects: 320
Study 20090775 — intervention group
Group type: EXPERIMENTAL
Intervention: Area method (AM)
Number of subjects: 320
Study 20090775 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke volume/pulse‐pressure method (SVPP)
Number of subjects: 320
Study 20090775 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 320
Study 20090775 — intervention group
Group type: COMPARATOR
Intervention: Correlation between methods
Number of subjects: 320
Study 20090775 — intervention group
Group type: COMPARATOR
Intervention: Subgroup analysis for cardiovascular risk
Number of subjects: 320
Study 20090775 — intervention group
Group type: COMPARATOR
Intervention: Echo parameters correlation
Number of subjects: 320
Study 17642399 — intervention group
Group type: EXPERIMENTAL
Intervention: Xolair (omalizumab)
Number of subjects: 33
Study 17642399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 15658946 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise and manipulative therapy
Number of subjects: 200
Study 15658946 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 200
Study 11858330 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopaedic Research Institute-Ankle Strength Testing System (ORI-ASTS)
Number of subjects: 11
Study 9794989 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard formula containing docosahexaenoic acid (DHA)
Number of subjects: 274
Study 9794989 — intervention group
Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 274
Study 9794989 — intervention group
Group type: COMPARATOR
Intervention: Standard formula containing DHA and arachidonic acid
Number of subjects: 274
Study 9794989 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized human milk comparison group
Number of subjects: 274
Study 7906279 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg SDZ CO 611
Number of subjects: 16
Study 7906279 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg SDZ CO 611
Number of subjects: 16
Study 7906279 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day SDZ CO 611
Number of subjects: 16
Study 2669553 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glucocorticosteroids
Number of subjects: 10
Study 2669553 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 236209 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 N NaHCO3 (alkaline solution)
Number of subjects: 30
Study 236209 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 30
Study 31408377 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidiabetic treatment with glyburide, metformin, or pioglitazone
Number of subjects: 0
Study 31408377 — intervention group
Group type: COMPARATOR
Intervention: MUO/T2D group
Number of subjects: 0
Study 31408377 — intervention group
Group type: COMPARATOR
Intervention: Lean subjects
Number of subjects: 0
Study 31408377 — intervention group
Group type: COMPARATOR
Intervention: MHO group
Number of subjects: 0
Study 28323952 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA diet (olive oil)
Number of subjects: 43
Study 28323952 — intervention group
Group type: COMPARATOR
Intervention: Fiber-rich diet
Number of subjects: 43
Study 28323952 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard US food)
Number of subjects: 43
Study 25487313 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 27
Study 25487313 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 27
Study 25487313 — intervention group
Group type: COMPARATOR
Intervention: OSAS patients before CPAP treatment
Number of subjects: 27
Study 24056618 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction followed by tacrolimus monotherapy
Number of subjects: 116
Study 24056618 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab induction followed by tacrolimus and MMF maintenance
Number of subjects: 116
Study 21401538 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg + Ondansetron 4 mg
Number of subjects: 130
Study 21401538 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron 4 mg
Number of subjects: 130
Study 19921359 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B+Mor+Mg (20 ml 0.25% bupivacaine, morphine 2 mg, magnesium 150 mg)
Number of subjects: 80
Study 19921359 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B+Mor (20 ml 0.25% bupivacaine, morphine 2 mg)
Number of subjects: 80
Study 19921359 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B+Mg (20 ml 0.25% bupivacaine, magnesium 150 mg)
Number of subjects: 80
Study 19921359 — intervention group
Group type: COMPARATOR
Intervention: Group B (20 ml 0.25% bupivacaine)
Number of subjects: 80
Study 16636839 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital color, red‐free and red light imaging
Number of subjects: 110
Study 16636839 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtraction method
Number of subjects: 110
Study 16636839 — intervention group
Group type: COMPARATOR
Intervention: Digital imaging
Number of subjects: 110
Study 14558954 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin 5,000 u/kg preoperatively
Number of subjects: 60
Study 14558954 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ulinastatin)
Number of subjects: 60
Study 10992996 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological lipid therapy
Number of subjects: 0
Study 10992996 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle changes
Number of subjects: 0
Study 10992996 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard lipid therapy in secondary prevention
Number of subjects: 0
Study 10992996 — intervention group
Group type: COMPARATOR
Intervention: Primary prevention lipid therapy
Number of subjects: 0
Study 9347245 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (TR), 200 mg once daily
Number of subjects: 23
Study 9347245 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 23
Study 8185689 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (maximal oral daily dose 200 mg)
Number of subjects: 80
Study 8185689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 8185689 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline
Number of subjects: 80
Study 2885450 — intervention group
Group type: EXPERIMENTAL
Intervention: Isovolaemic haemodilution
Number of subjects: 24
Study 2885450 — intervention group
Group type: COMPARATOR
Intervention: Sham dilutions (Control)
Number of subjects: 24
Study 29377462 — intervention group
Group type: EXPERIMENTAL
Intervention: selonsertib (SEL) 6 mg or 18 mg orally QD
Number of subjects: 72
Study 29377462 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum CK-18, IL-6 and CRP
Number of subjects: 72
Study 28826616 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (10 mg/day for 3 months, then escalated to 15 mg/day)
Number of subjects: 460
Study 28826616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 28826616 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 460
Study 27111772 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 231
Study 27111772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 23517884 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Number of subjects: 614
Study 23517884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 21585060 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint-catgut-embedment (ACE)
Number of subjects: 80
Study 21585060 — intervention group
Group type: COMPARATOR
Intervention: Medication (Rupixiao)
Number of subjects: 80
Study 19364999 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity advice and prescription by physicians (intervention group)
Number of subjects: 4317
Study 19364999 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 4317
Study 16937497 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical endoscopy
Number of subjects: 234
Study 16937497 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori test-and-treat
Number of subjects: 234
Study 16937497 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical prokinetic treatment with cisapride
Number of subjects: 234
Study 16937497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 234
Study 15291205 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of negative emotions (writing about unpleasant experiences)
Number of subjects: 32
Study 15291205 — intervention group
Group type: COMPARATOR
Intervention: Inhibition of negative emotions (suppressing emotional responses)
Number of subjects: 32
Study 15291205 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of emotions
Number of subjects: 32
Study 11368137 — intervention group
Group type: EXPERIMENTAL
Intervention: Carrier screening for fragile X syndrome, aspartylglycosaminuria, and infantile neuronal ceroid lipofuscinosis
Number of subjects: 256
Study 9272316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin ophthalmic solution (0.3%)
Number of subjects: 257
Study 9272316 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin ophthalmic solution
Number of subjects: 257
Study 8221366 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculokinetic perimetry (OKP) screener
Number of subjects: 75
Study 8221366 — intervention group
Group type: COMPARATOR
Intervention: Friedmann field analyser standard program
Number of subjects: 75
Study 8221366 — intervention group
Group type: COMPARATOR
Intervention: Humphrey field analyser 40-point screening program
Number of subjects: 75
Study 2891333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide-containing regimens (Regimens 1 to 4 combined)
Number of subjects: 833
Study 2891333 — intervention group
Group type: COMPARATOR
Intervention: Nonpyrazinamide series (Regimen 5)
Number of subjects: 833
Study 2891333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide series
Number of subjects: 833
Study 2891333 — intervention group
Group type: COMPARATOR
Intervention: Nonpyrazinamide series
Number of subjects: 833
Study 2891333 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinamide series (for patients with strains resistant to isoniazid, streptomycin, or both)
Number of subjects: 833
Study 28923985 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamping after at least 2 minutes and immediate neonatal care with cord intact
Number of subjects: 261
Study 28923985 — intervention group
Group type: COMPARATOR
Intervention: Clamping within 20 seconds and immediate neonatal care after clamping
Number of subjects: 261
Study 28002709 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate for 5 days
Number of subjects: 520
Study 28002709 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin‐clavulanate for 10 days
Number of subjects: 520
Study 24078373 — intervention group
Group type: EXPERIMENTAL
Intervention: Family skills training intervention (SFP 10-14) in 10 schools with 371 students
Number of subjects: 587
Study 24078373 — intervention group
Group type: COMPARATOR
Intervention: Control group in 9 schools with 216 students
Number of subjects: 587
Study 22222208 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 126
Study 22222208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intolerance-of-uncertainty therapy (IUT)
Number of subjects: 126
Study 22222208 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment (DT)
Number of subjects: 126
Study 20363092 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus varenicline
Number of subjects: 542
Study 18691579 — intervention group
Group type: COMPARATOR
Intervention: Endoluminal image analysis using capsule technology (Pillcam)
Number of subjects: 86
Study 15820911 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 49
Study 15820911 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 49
Study 15820911 — intervention group
Group type: COMPARATOR
Intervention: Comparison of real and placebo acupuncture
Number of subjects: 49
Study 12671113 — intervention group
Group type: EXPERIMENTAL
Intervention: GlucoWatch biographer
Number of subjects: 40
Study 12671113 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 40
Study 11029132 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol gel hand sanitizer used by students and staff when entering and leaving the classroom.
Number of subjects: 6000
Study 11029132 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alcohol gel hand sanitizer used).
Number of subjects: 6000
Study 11029132 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol gel hand sanitizer used in schools with the largest teacher population (n = 246).
Number of subjects: 6000
Study 8640699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole HCL, 1 mg twice daily
Number of subjects: 683
Study 8640699 — intervention group
Group type: COMPARATOR
Intervention: Megestrol acetate, 40 mg 4 times daily
Number of subjects: 683
Study 7690082 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.5 micrograms/kg
Number of subjects: 7
Study 7690082 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 micrograms/kg
Number of subjects: 7
Study 7690082 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms/kg
Number of subjects: 7
Study 7690082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3535990 — intervention group
Group type: EXPERIMENTAL
Intervention: One year's adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5‐fluorouracil
Number of subjects: 0
Study 3535990 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study 3535990 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by chemotherapy
Number of subjects: 0
Study 29670330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (120 mg/day)
Number of subjects: 60
Study 27128642 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource Mothers Program (RMP) home visiting
Number of subjects: 150
Study 27128642 — intervention group
Group type: COMPARATOR
Intervention: Telephone support control group
Number of subjects: 150
Study 25037843 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach model (individualized in-home strategy; n = 125)
Number of subjects: 246
Study 25037843 — intervention group
Group type: COMPARATOR
Intervention: Center model (community center largely with groups; n = 121)
Number of subjects: 246
Study 23053830 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-located behavioral health services in primary care practices
Number of subjects: 0
Study 23053830 — intervention group
Group type: COMPARATOR
Intervention: Enhanced referral procedure for external locations
Number of subjects: 0
Study 23053830 — intervention group
Group type: COMPARATOR
Intervention: Referral as usual to regional children's hospital
Number of subjects: 0
Study 20347544 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Shunting (RS)
Number of subjects: 200
Study 20347544 — intervention group
Group type: COMPARATOR
Intervention: Selective Shunting (SS)
Number of subjects: 200
Study 18512141 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational workshops (n = 52)
Number of subjects: 107
Study 18512141 — intervention group
Group type: COMPARATOR
Intervention: Control video session (n = 55)
Number of subjects: 107
Study 15936729 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hertz left temporoparietal repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 50
Study 15936729 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 50
Study 12817758 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily for 3 years
Number of subjects: 693
Study 12817758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 693
Study 10100116 — intervention group
Group type: EXPERIMENTAL
Intervention: Sagittal plane hold-relax exercise
Number of subjects: 60
Study 10100116 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretch
Number of subjects: 60
Study 10100116 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 8866927 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC-free metered-dose inhaler (CFC-free)
Number of subjects: 12
Study 8866927 — intervention group
Group type: COMPARATOR
Intervention: CFC metered-dose inhaler (CFC)
Number of subjects: 12
Study 8866927 — intervention group
Group type: COMPARATOR
Intervention: Dry powder inhaler (DPI)
Number of subjects: 12
Study 1801963 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine maleate (50 mg, tablet) after overnight fast
Number of subjects: 12
Study 1801963 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine maleate (50 mg, tablet) after breakfast
Number of subjects: 12
Study 6144244 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 103
Study 6144244 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Therapy (R)
Number of subjects: 103
Study 6144244 — intervention group
Group type: COMPARATOR
Intervention: Supportive Therapy of Dynamic Type (ST)
Number of subjects: 103
Study 6144244 — intervention group
Group type: COMPARATOR
Intervention: Basal Therapy (B)
Number of subjects: 103
Study 31624633 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04895162
Number of subjects: 0
Study 31624633 — intervention group
Group type: EXPERIMENTAL
Intervention: DILIsym modeling
Number of subjects: 0
Study 31624633 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated human hepatotoxicity
Number of subjects: 0
Study 31624633 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher PF-04895162 liver exposures
Number of subjects: 0
Study 29956827 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Number of subjects: 647
Study 26762838 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC group)
Number of subjects: 100
Study 26762838 — intervention group
Group type: COMPARATOR
Intervention: Anti-TNF agents (anti-TNF group)
Number of subjects: 100
Study 25384473 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-spinning platelet-enriched gel (PRP) with leukocytes
Number of subjects: 150
Study 25384473 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-spinning platelet-rich preparation (PRGF Endoret® Technology) without leukocytes
Number of subjects: 150
Study 25384473 — intervention group
Group type: COMPARATOR
Intervention: Non-gel group (control)
Number of subjects: 150
Study 21859193 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive appraisal training
Number of subjects: 0
Study 21859193 — intervention group
Group type: COMPARATOR
Intervention: Negative appraisal training
Number of subjects: 0
Study 20509875 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (1 g daily)
Number of subjects: 12513
Study 20509875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12513
Study 17885551 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor ramipril
Number of subjects: 347
Study 17885551 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous ACE haplotypes
Number of subjects: 347
Study 16193341 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g L-carnitine
Number of subjects: 12
Study 16193341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12114339 — intervention group
Group type: EXPERIMENTAL
Intervention: Rollator
Number of subjects: 40
Study 12114339 — intervention group
Group type: COMPARATOR
Intervention: Unaided 6MWT
Number of subjects: 40
Study 10434221 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate (12.5 mg, 25 mg, 50 mg, or 100 mg)
Number of subjects: 620
Study 10434221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 7599221 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (100 mg daily for three months)
Number of subjects: 27
Study 7599221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2189951 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (40 mg daily) for 2 or 5 years
Number of subjects: 75
Study 2189951 — intervention group
Group type: COMPARATOR
Intervention: Control (no adjuvant endocrine therapy)
Number of subjects: 75
Study 708560 — intervention group
Group type: EXPERIMENTAL
Intervention: Three formulations of etomidate
Number of subjects: 0